Established 2025
Three Lakes 12-20 (TL 12-20) is a public research foundation focused on advancing therapies for pulmonary fibrosis (PF) and interstitial lung disease (ILD). Our mission, similar to that of its predecessor, Three Lakes Foundation, is to accelerate the development of effective treatments and translational tools by supporting innovative science and bridging promising ideas with clinical validation.
Operating within the New Venture Fund, a free-standing 501(c)(3) public charity, TL 12-20 is committed to transforming the future of care for PF and ILD patients, caregivers, and clinicians—driven by urgency, collaboration, and a deep dedication to improving lives.
Until every person can breathe freely, we refuse to sit still.
Our Team
Payton Hillman
Payton Hillman
Chloe Wilson
Payton Hillman
Jessica Davis
Payton Hillman
James Williams
Payton Hillman
Understanding Our Mission
At Three Lakes 12-20, our mission is to accelerate development of effective therapies and translational resources for pulmonary fibrosis and ILD.
100,000+
Number of US Patients with pulmonary fibrosis
3-5 Years
Median Remaining Survival Years After Diagnosis
38%
Patients who need supplemental oxygen within 2 years of diagnosis
25-30%
Patients who will be referred for a lung transplant
Accelerating Research
Three Lakes 12-20 will focus on accelerating research and drug development by validating and improving access to human tissues and assays and by supporting the development of IND-enabling studies and early clinical trials. This work will not only attract additional funding for fibrotic diseases but will ultimately lead to safer and more effective treatment options.
PF COLLECT
Pulmonary Fibrosis Consortium for Living Lung Excised Tissue
Human Precision Cut Lung Slices (hPCLS) have been developed as a way to assess efficacy of novel IPF therapies but access to this model is limited. The PF-COLLECT Consortium will consist of Pharmaceutical and Foundation Members who will collaborate to validate cryopreservation and develop human based tissue resources and assays to accelerate the development of therapies for ILD and PF. Being able to store the tissue for an extended period of time will speed up drug discovery by making tissues readily accessible and enabling tissue to be banked for future studies.
Our Initiatives
We are committed to continuing and expanding the pivotal work of Three Lakes Foundation to accelerate therapies for pulmonary fibrosis. Our passion and focus is on enhancing the drug development path to improve quality and quantity of effective safe therapies.
Come Meet With Us
Upcoming Events
Boston, MA
August 19-20: See the Recap
Accelerating Pulmonary Fibrosis Therapeutics from Discovery to Reality: Assessing Emerging Biological Understanding, Evaluating Combination Therapy, & Delineating Endpoints Including & Beyond FVC for Transformative Efficacy
Rochester, MN
October 17 - 18
The Team Telomere Micro Meeting 2025 is a focused and collaborative gathering designed to bring together members of the scientific and clinical community to advance research and care for Telomere Biology Disorders. This two-day event will include expert talks, in-depth discussions, breakout sessions, community perspectives, and networking opportunities to drive actionable progress in diagnosis, management, and treatment.
Chicago, IL
November 13-15
PFF Summit is the world’s largest conference focused on pulmonary fibrosis (PF) and interstitial lung disease (ILD) research and education. Held every other year, it unites the community to come together as one to learn about this disease from globally recognized experts.
